

Symptom Control & Quality of Life Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Friday, May 12, 2023 7:30 am - 9:30 am
 Room: Garden Room (Atrium Lobby Level)

Agenda

Plenary Presentation:

Complex Care Issues for Individuals Living with Advanced and Metastatic Cancers, Michelle A. Mollica PhD, MPH, RN, OCN

Active Trials

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Activated: 2/21/19; Temporarily closed: 8/9/22.

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Drs. Accordino, Pennington, Hershman, et al.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Drs. Henry, Hershman, and Skaar.

Other Concepts in Development

Acupuncture to decrease symptom burden in patients with metastatic breast cancer. Dr. Greenlee

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational, cognitive rehabilitation program to improve perceived cognitive function for cancer survivors. Dr. Myers

Closed Trials

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al.

Permanently closed 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

S0702, "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak, Activated: 12/15/08. Closed: 12/13/13.

S1200, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Dr. Hershman. Activated: 3/27/12. Closed: 2/15/17.

Committee Business

1. What is happening with our open studies?
2. What other studies are we planning?
3. What other updates should we know about
 - Patient Advocate update
 - Statistical Center update

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

Symptom Control & Quality of Life Committee

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

GU

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Dr. Chapin. Activated: 9/17/18.

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Dr. Singh. Activated: 4/19/18.

Leukemia

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

Lymphoma

S1826, “A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.” Drs. Herrera, Friedberg. Activated: 7/19/19.

S1918, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma

S1803, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

Prevention and Epidemiology

S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).” Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE).” Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

NCTN Studies

CTSU/NRG-GI004, “Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.” Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1600	S1614	S1714	S2013	A221505	A221602	A221702	A221805	A222004	EAQ202	EAZ171	NRGCC010
Ascension Providence Hosp - Southfield	-	-	-	15	-	-	-	-	-	-	-	-
Ascension Via Christi Hosp Wichita	-	-	1	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hosp	-	-	-	1	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	3	-	1	2	-	-	-	-
Ca Res Consort of W Mich NCORP	-	-	146	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	10	1	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	38	-	-	-	-	-	-	-	-
Carle CC NCORP	-	-	6	3	-	-	-	-	-	-	-	-
City of Hope CCC	6	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	27	14	-	3	-	-	-	-	-	-
Columbus NCORP	-	-	-	17	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	-	71	9	-	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	1	-	1	-	-	-	-
Desert Regional Med Ctr	-	-	3	-	-	3	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	10	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	-	18	35	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	10	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	1	-	26	12	1	-	-	-	-	-	1	2
Hawaii MU NCORP	-	-	70	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	38	99	-	-	-	-	-	-	-	-
Henry Ford Hosp	8	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Caologia	-	-	10	-	-	-	-	-	-	-	-	-
Instituto Nacional De Caologia de Mexico	-	-	60	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	2	65	15	-	-	-	-	-	-	-	-
Lahey Hosp and Med Ctr	-	-	22	29	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	-	2	-	-	-	-	-	-	-	-	-
Massachusetts Veterans ERIC	-	-	-	15	-	-	-	-	-	-	-	-

Symptom Control & Quality of Life Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1600	S1614	S1714	S2013	A221505	A221602	A221702	A221805	A222004	EAQ202	EAZ171	NRGCC010
Med U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	2	-
Montana Ca Consort NCORP	-	-	-	2	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	-	30	-	-	-	-	-	-	39	-	-
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-	-	4	-	-
Northwell Hlth NCORP	-	-	-	-	2	3	-	-	-	-	-	-
Oregon Hlth and Science U	-	-	-	12	-	-	-	-	-	-	-	-
Pacific Ca Res Consort NCORP	-	-	2	1	-	-	-	-	-	-	-	-
STCC at DHR Hlth Inst for Res and Dev	-	-	-	3	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	278	60	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	6	-	-	-	-	-	-	-
Tulane U Hlth Sciences Ctr	-	-	1	-	-	-	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	4	1	4	-	-	-	-	-	-
USC Norris CCC LAPS	63	-	-	1	-	-	-	-	-	-	-	-
U Arkansas for Med Sciences	-	-	68	10	-	-	-	-	-	-	-	-
U Colorado CC LAPS	8	-	2	-	16	-	1	2	-	-	-	-
U Kansas CC - MCA Rural MU NCORP	45	-	24	14	-	-	-	2	-	-	-	-
U Kentucky/Markey CC	-	-	-	-	-	10	-	-	-	-	-	-
U Rochester LAPS	11	-	-	-	-	-	14	-	-	-	-	-
U Texas HSC at San Antonio	-	-	14	18	-	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	1	-	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	-	-	8	-	-	2	-	-	-
Upstate Carolina NCORP	-	-	118	-	1	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	-	-	1	-	-	-	-	-
Wisconsin NCORP	-	-	-	9	-	-	-	-	-	-	-	-
ALLIANCE	5	-	44	77	-	-	-	-	-	-	-	-
ECOG-ACRIN	1	-	80	42	-	-	-	-	-	-	-	-
NRG	2	1	90	62	-	-	-	-	-	-	-	-
Total	160	4	1,336	618	30	32	17	7	2	43	3	2